EGFR and non-small cell squamous lung carcinoma: Necitumumab's indication refers to “epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer” with no reference to activating mutations, thus there is no reference to the need of a validated test in section 4.2 and/or 4.4.